SPPI Stock - Spectrum Pharmaceuticals, Inc.
Unlock GoAI Insights for SPPI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $10.11M | N/A | N/A | $22.61M | $109.33M |
| Gross Profit | $8.32M | N/A | N/A | $10.61M | $82.58M |
| Gross Margin | 82.3% | N/A | N/A | 46.9% | 75.5% |
| Operating Income | $-72,697,000 | $-147,703,000 | $-169,734,000 | $-144,033,000 | $-131,177,000 |
| Net Income | $-78,104,000 | $-158,436,000 | $-171,272,000 | $-135,386,000 | $-120,011,000 |
| Net Margin | -772.2% | N/A | N/A | -598.7% | -109.8% |
| EPS | $-0.43 | $-1.02 | $-1.38 | $-1.22 | $-1.16 |
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 26th 2023 | JMP Securities | Downgrade | Market Perform | - |
Earnings History & Surprises
SPPIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 7, 2024 | — | — | — | — |
Q1 2024 | Mar 20, 2024 | — | — | — | — |
Q4 2023 | Nov 8, 2023 | $-0.02 | — | — | — |
Q3 2023 | Aug 10, 2023 | $-0.04 | $-0.17 | -325.0% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.05 | $-0.02 | +60.0% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $-0.09 | $-0.06 | +33.3% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.15 | $-0.12 | +20.0% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.16 | $-0.17 | -6.3% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.18 | $-0.09 | +50.0% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-0.21 | $-0.26 | -23.8% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.30 | $-0.21 | +30.0% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.24 | $-0.32 | -33.3% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-0.33 | $-0.25 | +24.2% | ✓ BEAT |
Q4 2020 | Dec 31, 2020 | — | $-0.28 | — | — |
Q4 2020 | Nov 4, 2020 | $-0.37 | $-0.37 | 0.0% | = MET |
Q3 2020 | Aug 10, 2020 | $-0.33 | $-0.29 | +12.1% | ✓ BEAT |
Q2 2020 | May 7, 2020 | $-0.34 | $-0.36 | -5.9% | ✗ MISS |
Q1 2020 | Feb 27, 2020 | $-0.22 | $-0.30 | -36.4% | ✗ MISS |
Q4 2019 | Nov 7, 2019 | $-0.26 | $-0.22 | +15.4% | ✓ BEAT |
Q3 2019 | Aug 8, 2019 | $-0.32 | $-0.23 | +28.1% | ✓ BEAT |
Frequently Asked Questions about SPPI
What is SPPI's current stock price?
What is the analyst price target for SPPI?
What sector is Spectrum Pharmaceuticals, Inc. in?
What is SPPI's market cap?
Does SPPI pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SPPI for comparison